The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk
Subscribe To Our Newsletter & Stay Updated